Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant asparaginase versus Asparaginase medac in children with newly diagnosed acute lymphoblastic leukemia
NL-OMON24878Phase 2Active, not recruiting
- Sponsor
- medac
- Start
- Nov 2004
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of asparaginase escherichia coli in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by medac. Primary endpoint: 72-hour serum concentration-time exposure. Started Nov 2004; status: active, not recruiting.
02
Drugs
asparaginase escherichia coli
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON24878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24878.